JOHNSON & JOHNSON

Johnson & Johnson reported Q3 2026 results with sales up 5.9% to $25.4 billion, driven by operational growth in both Innovative Medicine and MedTech segments. However, adjusted EPS decreased by 7.5% to $2.59 due to one-time charges. The company raised its full-year 2026 guidance, expecting reported sales between $101.0B - $101.4B. Key developments include the acquisition of Firefly Bio, Inc., a collaboration with Sail Biomedicines, and significant regulatory approvals for new treatments and devices.

Johnson & Johnson announced that Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine, will retire effective September 1, 2026. Taubert had a distinguished 21-year career, during which she grew the Innovative Medicine business to over $60 billion in annual revenue. Tom Cavanaugh, currently Company Group Chairman, North America, Innovative Medicine, will succeed her and join the Executive Committee, ensuring a smooth leadership transition.

Johnson & Johnson announced the completion of its acquisition of Firefly Bio, Inc. for $1 billion and entered into strategic agreements and collaboration with Sail Biomedicines, including a $465 million equity investment and an exclusive option to acquire Sail for $2.58 billion. These transactions are expected to reduce the company's 2026 Adjusted Operational EPS and Adjusted EPS by approximately $0.64, and by approximately $1.36 in 2027. As a result, J&J updated its full-year 2026 guidance, lowering the Adjusted Operational EPS midpoint from $11.58 to $10.94 and Adjusted EPS midpoint from $11.68 to $11.04.

Johnson & Johnson announced a comprehensive resolution for the ovarian talc litigation, committing $5.5 billion. The agreement, contingent on 95% claimant participation, includes a first payment of up to $3 billion in 2027, with no further payments before 2028. This resolution follows a favorable MDL court ruling regarding specific causation and aims to conclude the 15-year litigation, which the company states lacked scientific merit.

Johnson & Johnson reported a 6.6% increase in second-quarter sales to $25.31 billion, with net earnings remaining largely flat at $5.53 billion. For the six months, sales grew 8.2% to $49.37 billion, while net earnings decreased significantly to $10.77 billion, primarily due to a large "other income" in the prior year. The company also highlighted risks related to the planned separation of its Orthopaedics business.

Johnson & Johnson reported strong second-quarter 2026 results, with reported sales increasing 6.6% to $25.3 billion and adjusted EPS rising 4.7% to $2.90. The company raised its full-year 2026 guidance, now expecting reported sales of $101.1 billion and adjusted EPS of $11.68 at the midpoint. This performance was driven by robust growth in both the Innovative Medicine and MedTech segments, alongside significant innovation with multiple product approvals and pipeline advancements.

JOHNSON & JOHNSON held its 2026 Annual Meeting of Shareholders on April 23, 2026. Shareholders elected all 12 director nominees, approved the executive compensation on an advisory basis, and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026. Additionally, a shareholder proposal to adopt a policy requiring an independent board chair was not approved.

Johnson & Johnson submitted its Quarterly Report on Form 10-Q for the fiscal quarter ended March 29, 2026. The filing confirms the company's status as a large accelerated filer and includes its consolidated financial statements. As of April 17, 2026, the company reported 2,407,216,971 shares of common stock outstanding.

Johnson & Johnson announced a 3.1% increase in its quarterly dividend, raising it from $1.30 to $1.34 per share. This marks the 64th consecutive year of dividend increases for the company, demonstrating a consistent return to shareholders. The new annual dividend rate will be $5.36 per share, payable on June 9, 2026, to shareholders of record on May 26, 2026. The company also announced its first-quarter 2026 sales and earnings.

Johnson & Johnson announced a 3.1% increase in its quarterly dividend, raising it from $1.30 to $1.34 per share. This marks the 64th consecutive year the company has increased its dividend, reflecting a strong commitment to shareholder returns. The new annual dividend rate will be $5.36 per share, payable on June 9, 2026, to shareholders of record as of May 26, 2026. The company also announced its first-quarter 2026 sales and earnings.